>

Eli Lilly Profile

<div class='circular--portrait' style='background:#754DEB;color: white;font-size:3em;padding-top: 40px;;'>ELI</div>

Performance

20 / 100

Odds of Distress

8
Equity ratings for Eli Lilly And Company are calculated based on Macroaxis scoring framework. The performance scores are derived for the period starting November 23, 2019 and ending today February 21, 2020. Click here to learn more.

Eli Lilly Profile

Next fiscal quarter end is expected on March 31, 2020. Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana. Eli Lilly operates under Drug ManufacturersGeneral classification in USA and is traded on BATS Exchange. It employs 33625 people. more on Eli Lilly
Eli Lilly Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
Eli Lilly And SEC Filings
Eli Lilly SEC Filings
Security & Exchange Commission EDGAR ReportsView All
Legal NameEli Lilly And Company
Older SymbolLLY
PresidentJoshua SmileyView All
Thematic Classifications
Active investing themes Eli Lilly currently participates. An investing theme is an unweighted collection of funds, stocks, ETFs or cryptocurrencies
    Healthcare
    Compulsion
showing 2 out of 3 themes  View All
Average Analyst Recommendation
Current trade recommendation based on an ongoing consensus estimate among financial analysis covering Eli Lilly And
Piotroski F Score
Academic score to determine the current strength of Eli Lilly And financial position
Macroaxis Advice
Macroaxis buy hold or sell recommendation provided in the context of your current investment horizon and risk tolerance.
Horizon: 30 days (very short)Advice
Financial Strength
Eli Lilly And ability to generate sufficient cash flow to pay bills, repay debt, and make consistent year-to-year profit
Total Debt
Debt Current
Debt Non Current
Long Term Debt to Equity
Debt to Equity Ratio
Return on Investment
Return on Average Assets
Return on Average Equity
Return on Invested Capital
Return on Sales
Earnings per Basic Share
Earnings per Diluted Share
Price to Earnings Ratio
Earnings before Tax
Average Bond Rating: AA-Very Strong
Profitability
Few selected profitability drivers of Eli Lilly representing accounts that assess its ability to generate profits relative to its revenue, operating costs, and shareholders' equity
Consolidated Income
Net Income
Net Income Common Stock
Operating Income
Income Tax Expense
Net Income Per Employee
Operating Margin
EBITDA Margin
Gross Margin
Profit Margin
Eli Lilly And Company (LLY) is traded on BATS Exchange in USA. It is located in Lilly Corporate Center, Indianapolis, IN 46285, United States and employs 33,625 people. Eli Lilly And Company was previously known as ELI LILLY Co and was traded on BATS Exchange under the symbol LLY. Eli Lilly is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Mega-Cap' category with total capitalization of 125.88 B. Eli Lilly And runs under Healthcare sector within Drug Manufacturers?General industry. The entity has 960.13 M outstanding shares of which 12.57 M shares are now shorted by investors with about 3.57 days to cover shorted positions. LILLY ELI CO has about 1.7 B in cash with 3.57 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.77.
Check Eli Lilly Probability Of Bankruptcy

Ownership Allocation (%)

Eli Lilly Target Price Odds Analysis

Odds Below 142.26HorizonTargetOdds Above 142.26
83.81%30 days 142.26 16.08%
Based on normal probability distribution, the odds of Eli Lilly to move above current price in 30 days from now is about 16.08 (This Eli Lilly And Company probability density function shows the probability of Eli Lilly Stock to fall within a particular range of prices over 30 days) .

Eli Lilly And Top Holders

Eli Lilly Major Institutional Holders

InstituionSecurity TypeTotal SharesValue
Lilly Endowment IncCommon Shares114.6 M15.1 B
Blackrock IncCommon Shares60.9 MB
View Eli Lilly Diagnostics

Eli Lilly And Company Income Statement Over Time

Direct Expenses    Earning Before Interest and Taxes EBIT    Net Income    

Eli Lilly Against Markets

Did you try this?

Run Portfolio Holdings Now

   

Portfolio Holdings

Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
All  Next Launch Module

Eli Lilly Upcoming and Recent Events

Eli Lilly Company Earnings Announcements Dates

Upcoming Quarterly Earning ReportMay 5, 2020
Next Earnings ReportAugust 4, 2020
Next Fiscal Quarter EndMarch 31, 2020
Next Fiscal Year EndFebruary 4, 2021
Last Quarter Report DateDecember 31, 2019
Last Earning Anouncement DateMarch 31, 2019

Eli Lilly Corporate Filings

Eli Lilly SEC Reporting

Unclassified Corporate Event
Financial Statements and Exhibits. Results of Operations and Financial Condition
Submission of Matters to a Vote of Security Holders
Results of Operations and Financial Condition

Eli Lilly Distributions to stockholders

Eli Lilly Corporate Directors

Ellen Marram Lead Independent Director
Kathi Seifert Independent Director
Ralph Alvarez Independent Director
Additionally see Stocks Correlation. Please also try Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Company logos by clearbit